Is it sufficient to evaluate metastatic bone involvement in breast cancer using SPECT/CT? A new approach of SPECT/CT-guided targeted bone marrow biopsy

Li, Xiaomin; Chen, An; Zhang, Wanchun

doi:10.1186/s12885-022-09702-1

Cited by 6 publications

(8 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There are few reports on SPECT/CT guided percutaneous biopsy. Zhao YJ et al [27] applied SPECT/CT to thoracic tumor percutaneous biopsy, and Li X et al [12] applied SPECT/CT guided bone biopsy to the diagnosis of breast cancer patients with bone metastasis, proving its safety and reliability.…”

Section: Discussionmentioning

confidence: 99%

“…Nuclear medicine molecular imaging has unique advantages with respect to target area selection. In previous study, SPECT/CT-guided targeted BMB was con rmed to be a safe and feasible technique for the appraisal of breast cancer [12]. We conducted SPECT/CT guided BMB on suspected bone metastases in lung cancer, and tested its feasibility and clinical value in this study.…”

Section: Introductionmentioning

confidence: 98%

See 1 more Smart Citation

Clinical application of SPECT/CT guided targeted bone marrow biopsy in bone metastasis involvement in lung cancer

Li,

Zhang,

2024

Preprint

Self Cite

View full text Add to dashboard Cite

Objective To investigate the feasibility, safety, and clinical application value of single photon emission computed tomography/computed tomography (SPECT/CT)-guided bone marrow biopsy (BMB) in lung cancer (LC) patients with suspected bone metastases (BM) and compare its diagnostic performance for detection of BM with SPECT/CT. Methods The records of lung cancer patients referred for bone scintigraphy (BS), SPECT/CT and SPECT/CT-guided BMB from July of 2020 to July of 2023 in our hospital were retrospectively reviewed. 35 Patients were consecutively included in this study, all 34 specimens were analyzed by pathological and immunohistochemical studies.The biopsy success rate, total examination time, biopsy operation time, complications, CT radiation dose, and pathological and immunohistochemical results were recorded. The diagnostic performance based on SPECT/CT and SPECT/CT-guided BMB were compared with pathological, immunohistochemical examinations and the results of subsequent follow-up. Results Bone samples of the sites with high uptake were obtained in 34 patients under BMB, with a success rate of 97.1%(34/35). No severe postoperative complications occurred. Among all 34 cases, 29 specimens were positive for metastatic lung cancer (85%, 29/34), and positive for benign tissue in 5 cases (15%, 5/34). The average total examination time of 24 patients was (46.2 ± 7.3) minutes, and the biopsy operation time was (31.4 ± 8.2) minutes; The effective radiation dose generated during the entire inspection process is (2.2 ± 0.9) mSv. SPECT/CT-guided BMB demonstrated significantly higher negative predictive value (NPV) when compared to SPECT/CT (p = 0.021 < 0.05). The sensitivity, specificity, and negative predictive value (NPV) of BMB guided by SPECT/CT were significantly higher than those of SPECT/CT (p < 0.05). Conclusion It is insufficient to evaluate BM in LC patients using 99mTC-MDP SPECT/CT imaging. SPECT/CT-guided BMB was safe, accurate, and feasible and provided significantly higher sensitivity and NPV when compared to SPECT/CT for detection of BM in LC patients. In addition, our study initially showed the integrated approach that includes SPECT /CT and SPECT/CT-guided BMB, which can obtain one-stop imaging, pathological and molecular typing diagnosis in nuclear medicine department and offer important opportunities for precision treatment to improve quality of life of LC patients with BM.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 98%

Clinical application of SPECT/CT guided targeted bone marrow biopsy in bone metastasis involvement in lung cancer

Li,

Zhang,

2024

Preprint

Self Cite

View full text Add to dashboard Cite

show abstract

“…Radionuclide bone imaging, exempli ed by whole body static imaging (WBS), furnishes insights into osteoblast activity and vascular networks within the skeleton. This technique exhibits a proclivity for tracer absorption at locales of vigorous bone formation 14,15 . Although it maintains popularity among clinicians, it is deemed relatively insensitive and non-speci c in the assessment of systemic treatment responses to bone metastases.…”

Section: Discussionmentioning

confidence: 99%

FDG PET/CT, Precise Positioning of the Criminal Focus in the Osteogenic Region of Breast Cancer Bone Metastases after Therapy

Lin,

Lv,

et al. 2023

Preprint

View full text Add to dashboard Cite

Purpose The present study endeavours to investigate the utility and indispensability of FDG PET/CT in appraising the post-treatment efficacy of bone metastasis in cases of breast cancer. Method A cohort of 11 patients diagnosed with breast cancer and suffering from bone metastases was enrolled for this investigation. These patients underwent repeated FDG PET/CT evaluations, with comprehensive clinical records and sufficient follow-up duration available. Division of patients and bone metastases ensued into three distinct groups - amelioration, stability, and progression - predicated upon the response exhibited by each bone metastatic site subsequent to treatment. The ensuing analysis and juxtaposition encompassed PET and CT image alterations, levels of serum tumour biomarkers (CEA, CA153), as well as biochemical indicators (ALP, Ca), within each group across the identical time frame. Furthermore, the inquiry scrutinized disparities between immunohistochemical outcomes of primary breast cancer and bone metastases displaying escalated FDG uptake as discerned through PET/CT post-treatment. Results Discernible disparities in serological indices (CEA, CA153, ALP, and Ca) were absent among patients classified under distinct efficacy categories (p > 0.05). Nonetheless, diminished expression of Her-2 engendered an elevated likelihood of suboptimal efficacy (p < 0.05). Appraisal of efficacy, guided by individual bone metastases, unveiled notable fluctuations in FDG uptake through PET (SUVmax) amid the three groups (p < 0.05), while density variations in CT scans did not reach statistical significance (p = 0.243). Variances surfaced in FDG uptake, alterations in CT density, and levels of CEA and CA153 within patient sera before and after treatment (p < 0.05). Of these indicators, paramount diagnostic efficacy was ascribed to FDG PET metrics: alterations in FDG uptake (AUC 0.972) and post-therapy SUVmax (AUC 0.949). Immunohistochemical examination of bone metastases within the progressive group diverged from primary lesions. Conclusions FDG PET/CT confers precise assessment of the post-treatment efficacy pertaining to each bone metastatic site in breast cancer cases. The modality facilitates identification of eluding foci following extant therapies, localization for pathological assessment, and bears substantive significance in evaluating therapeutic efficacy, refining treatment stratagems, and prognosticating the trajectory for breast cancer patients contending with bone metastases.

show abstract

“…It has a significant influence on the quality of sustenance of life of women with breast cancer. Inflammation, pathological cracks, spinal stenosis, and hypokalemia of malignancies are clinical consequences of bone metastasis [ 53 ].…”

Section: Molecular Imaging Methods For Targeted Drug Deliverymentioning

confidence: 99%

Recent nanotheranostic approaches in cancer research

Gupta,

Roy,

Sharma

et al. 2024

Clin Exp Med

View full text Add to dashboard Cite

Humanity is suffering from cancer which has become a root cause of untimely deaths of individuals around the globe in the recent past. Nanotheranostics integrates therapeutics and diagnostics to monitor treatment response and enhance drug efficacy and safety. We hereby propose to discuss all recent cancer imaging and diagnostic tools, the mechanism of targeting tumor cells, and current nanotheranostic platforms available for cancer. This review discusses various nanotheranostic agents and novel molecular imaging tools like MRI, CT, PET, SPEC, and PAT used for cancer diagnostics. Emphasis is given to gold nanoparticles, silica, liposomes, dendrimers, and metal-based agents. We also highlight the mechanism of targeting the tumor cells, and the limitations of different nanotheranostic agents in the field of research for cancer treatment. Due to the complexity in this area, multifunctional and hybrid nanoparticles functionalized with targeted moieties or anti-cancer drugs show the best feature for theranostics that enables them to work on carrying and delivering active materials to the desired area of the requirement for early detection and diagnosis. Non-invasive imaging techniques have a specificity of receptor binding and internalization processes of the nanosystems within the cancer cells. Nanotheranostics may provide the appropriate medicine at the appropriate dose to the appropriate patient at the appropriate time. Graphical abstract

show abstract

Is it sufficient to evaluate metastatic bone involvement in breast cancer using SPECT/CT? A new approach of SPECT/CT-guided targeted bone marrow biopsy

Cited by 6 publications

References 25 publications

Clinical application of SPECT/CT guided targeted bone marrow biopsy in bone metastasis involvement in lung cancer

Clinical application of SPECT/CT guided targeted bone marrow biopsy in bone metastasis involvement in lung cancer

FDG PET/CT, Precise Positioning of the Criminal Focus in the Osteogenic Region of Breast Cancer Bone Metastases after Therapy

Recent nanotheranostic approaches in cancer research

Contact Info

Product

Resources

About